Generation of duck cell lines
Inventors
Guehenneux, Fabienne • Moreau, Karine • Esnault, Magali • Mehtali, Majid
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
Core Innovation
The invention provides a method of making a duck cell line by isolating a duck embryo around oviposition, dissociating the embryo into cells, and seeding the dissociated cells in basal medium comprising insulin like growth factor 1 (IGF-1), ciliary neurotrophic factor (CNTF), animal serum, and a layer of feeder cells. The cells are cultured for at least one passage to establish a duck cell line while supporting growth using exogenous growth factors, feeder layer, and animal serum.
The method then establishes proliferation in basal medium without exogenous growth factors, a feeder layer, and animal serum by withdrawing IGF-1 and CNTF from the culture, progressively withdrawing the feeder cells, and progressively withdrawing the animal serum over several passages. The cells are further cultured for at least one passage after each progressive withdrawal step, and are adapted to suspension culture conditions to obtain a duck cell line capable of proliferating under these defined absence conditions.
A key aspect of the obtained duck cell line is that it does not produce replication-competent endogenous retrovirus particles. The method thereby yields continuous diploid duck cell lines derived from embryonic stem cells that avoid endogenous retrovirus particle production, including the absence of replication-competent endogenous retrovirus particles associated with avian endogenous retrovirus families such as ALV-E and/or EAV.
Claims Coverage
The partial content identifies one independent claim covering a method of making a duck cell line that transitions from growth-factor/feeder/serum supported culture to basal-medium proliferation in suspension culture while preventing replication-competent endogenous retrovirus particle production. The main inventive features are described directly within the independent claim steps and corresponding dependent limitations listed in the partial claim set.
Duck cell line manufacturing with staged withdrawal and suspension adaptation
Isolating a duck embryo around oviposition, dissociating the embryo into cells, seeding in basal medium comprising IGF-1, CNTF, animal serum, and a layer of feeder cells, culturing for at least one passage, withdrawing IGF-1 and CNTF, progressively withdrawing feeder cells, progressively withdrawing animal serum, and adapting the cells to suspension culture conditions to obtain a duck cell line capable of proliferating in basal medium in the absence of exogenous growth factors, a feeder layer, and animal serum.
Duck cell line lacking replication-competent endogenous retrovirus particle production
Obtaining a duck cell line in which the duck cell line does not produce replication-competent endogenous retrovirus particles.
Exogenous retrovirus risk limitation via specific genome status
Using a duck cell line whose genome lacks proviral sequences of avian leucosis virus (ALV-E) and/or endogenous avian virus (EAV) that would be susceptible to producing replication-competent endogenous retroviral particles.
EBx duck cell line characterization constraints
The duck cell line has at least one specified characteristic, selected from endogenous telomerase activity, an approximately 10 µm diameter, a population doubling time of about 30 hours or less at 37°C, and/or expression of additional markers selected from alkaline phosphatase, SSEA-1, EMA-1, and ENS-1.
Simultaneous growth factor withdrawal
Withdrawing the IGF-1 and CNTF from the culture medium simultaneously.
Specified initial animal serum level and feeder cell type
Using basal medium in step c) with animal serum at a specified range and using feeder cells that are mitotically inactivated mouse fibroblast cells.
Overall, the claim coverage centers on a staged method that first supports duck embryo-derived cell growth using IGF-1, CNTF, animal serum, and feeder cells, then progressively removes these supports and adapts the cells to suspension culture so that proliferation occurs without exogenous growth factors, feeder layer, or animal serum, while the resulting duck cell line does not produce replication-competent endogenous retrovirus particles.
Stated Advantages
Enables a duck cell line that does not produce replication-competent endogenous retrovirus particles.
Documented Applications
Used for virus replication/titration and viral vaccine manufacturing, including production of poxvirus, influenza, Newcastle disease virus (NDV), and measles virus.
Interested in licensing this patent?